BOULDER, Colo., April 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2013 on Monday, May 6, 2013, and will hold a conference call on Tuesday, May 7, 2013 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer, and Michael Carruthers, Chief Financial Officer, will lead the call.
Conference Call Information
Date: Tuesday, May 7, 2013
Time: 9:00 a.m. eastern time
Toll-Free: (800) 446-1671
Toll: (847) 413-3362
Pass Code: 34484588
Webcast & Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company with significant progress toward generating data to support its upcoming Phase 3 / pivotal trial decisions. Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in both NRAS- and BRAF-mutant melanoma in 2013. AstraZeneca expects to begin Phase 3 or pivotal trials with Array-invented selumetinib in non-small cell lung cancer and thyroid cancer during the second half of 2013. Three other Array invented drugs are also approaching Phase 3 / pivotal trial decisions by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche). For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.
Tricia Haugeto, Array BioPharma Inc., (303) 386-1193, email@example.com